GlassScriptPhysician profile
Mary D Brown
NPI 1588987374
$1,208.81
in general payments reported to CMS, 2019-2025
19 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.28 · 2022: $696 · 2023: $146 · 2024: $214 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $262.71 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $151.80 | 2022 | |
| Abbott Laboratories | $142.75 | 2022-2024 | Amplatzer Talisman, Amplatzer Amulet, Diamondback Coronary |
| Amgen INC. | $132.16 | 2022-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $73.47 | 2022 | |
| Lilly USA, LLC | $57.62 | 2022 | |
| Inari Medical, INC. | $55.73 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mylan Specialty L.P. | $49.07 | 2024 | Yupelri |
| Abbvie INC. | $42.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.18 | 2022 | |
| Boston Scientific Corporation | $37.71 | 2024 | |
| Edwards Lifesciences Corporation | $30.92 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Currax Pharmaceuticals LLC | $26.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.95 | 2022 | |
| Amarin Pharma, INC. | $20.87 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $14.38 | 2022 | |
| Biosense Webster, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.